文献速递骨软组织肉瘤与黑色素瘤

预测II期黑色素瘤患者无复发生存与总生存:MIA计算器

Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
PubMed 文献 · J Clin Oncol · 2024-02-05

基于澳大利亚黑色素瘤研究所数据库3220例II期黑色素瘤患者,采用多变量Cox回归建立MIA模型预测5年及10年无复发生存与总生存,并在美国和荷兰数据集外部验证;MIA模型区分度优于AJCC-8分期模型,校准良好,可在有或无前哨淋巴结活检病理分期时提供个体化估计。

要点

  • MIA模型预测5年及10年无复发生存C统计量分别为0.70和0.73,优于AJCC-8分期模型的0.61和0.60。
  • MIA模型预测5年及10年总生存C统计量分别为0.71和0.75,优于AJCC-8分期模型的0.62和0.61。
  • MIA模型校准良好并经外部验证,可在有或无前哨淋巴结活检病理分期时使用。

核心结论

  • MIA模型对II期黑色素瘤患者的无复发生存和总生存提供准确且个体化的估计,即使未行前哨淋巴结活检病理分期亦然。
  • 这些模型在外部验证中表现稳健,可在日常实践中(理想情况下)有或无前哨淋巴结活检时用于识别高危患者以制定进一步管理策略。

研究设计与样本

  • 数据提取自澳大利亚黑色素瘤研究所(MIA)数据库,纳入诊断为II期(临床或病理)黑色素瘤患者n=3,220。
  • 采用多变量Cox回归分析建立生存预测模型(MIA模型),并使用美国和荷兰的数据集进行两次外部验证。
  • 每个模型的性能通过C统计量和校准图评估,并与基于AJCC-8分期的Cox模型(分期模型)比较。

主要发现

  • 5年和10年无复发生存C统计量:MIA模型分别为0.70和0.73,分期模型分别为0.61和0.60。
  • 5年和10年总生存C统计量:MIA模型分别为0.71和0.75,分期模型分别为0.62和0.61。
  • MIA模型校准良好并经外部验证。

临床怎么用

  • 作者指出MIA模型可在日常实践中(理想情况下)有或无前哨淋巴结活检时使用,以识别高危患者以制定进一步管理策略。
  • 在线工具将在MIA网站(Risk Prediction Tools)提供。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Improvements in recurrence-free survival (RFS) were demonstrated in two recent randomized trials for patients with sentinel node (SN)-negative stage IIB or IIC melanoma receiving adjuvant systemic therapy (pembrolizumab/nivolumab). However, adverse events also occurred. Accurate individualized prognostic estimates of RFS and overall survival (OS) would allow patients to more accurately weigh the risks and benefits of adjuvant therapy. Since the current American Joint Committee on Cancer eighth edition (AJCC-8) melanoma staging system focuses on melanoma-specific survival, we developed a multivariable risk prediction calculator that provides estimates of 5- and 10-year RFS and OS for these patients. METHODS: Data were extracted from the Melanoma Institute Australia (MIA) database for patients diagnosed with stage II (clinical or pathological) melanoma (n = 3,220). Survival prediction models were developed using multivariable Cox regression analyses (MIA models) and externally validated twice using data sets from the United States and the Netherlands. Each model's performance was assessed using C-statistics and calibration plots and compared with Cox models on the basis of AJCC-8 staging (stage models). RESULTS: The 5-year and 10-year RFS C-statistics were 0.70 and 0.73 (MIA-model) versus 0.61 and 0.60 (stage-model), respectively. For OS, the 5-year and 10-year C-statistics were 0.71 and 0.75 (MIA-model) compared with 0.62 and 0.61 (stage-model), respectively. The MIA models were well calibrated and externally validated. CONCLUSION: The MIA models offer accurate and personalized estimates of both RFS and OS in patients with stage II melanoma even in the absence of pathological staging with SN biopsy. These models were robust on external validations and may be used in everyday practice both with (ideally) and without performing SN biopsy to identify high-risk patients for further management strategies. An online tool will be available at the MIA website (Risk Prediction Tools).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Varey AHR, Li I, El Sharouni MA, et al. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. J Clin Oncol. 2024. PMID: 38315961. doi:10.1200/JCO.23.01020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。